MedTrace Logo

Single Embryo TrAnsfeR of Euploid Embryo

NCT02268786 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 661

Last updated 2020-05-13

Study results available
· View outcomes & findings →

Summary

The purpose of the current study is to evaluate the effect of preimplantation genetic screening (PGS) by next generation sequencing (NGS) compared to standard morphological assessment of embryos on pregnancy rates through a randomized controlled trial (RCT). All embryos will be vitrified and a single embryo transfer (SET) will be performed with either screened or unscreened embryos depending on randomization.

Conditions

Interventions

OTHER

Preimplantation Genetic Screening by NGS

The VeriSeq PGS takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for selection of euploid embryos.

Sponsors & Collaborators

  • Reprogenetics

    collaborator INDUSTRY

  • Genesis Genetics

    collaborator OTHER

  • Illumina, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States
  • Australia
  • Canada
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02268786 on ClinicalTrials.gov